HighTide Therapeutics-B (2511) Schedules 27 March 2026 Board Meeting to Approve FY 2025 Audited Results

Bulletin Express

03/13

HighTide Therapeutics, Inc. (HIGHTIDE-B, 2511) has announced that its board of directors will convene on Friday, 27 March 2026. The primary agenda is to review and approve the audited consolidated financial results for the year ended 31 December 2025 and authorise their publication. Additional routine business matters may also be addressed at the meeting.

The board currently consists of two executive directors (Dr. Liu Liping and Ms. Yu Meng), three non-executive directors (Dr. Zhu Xun, Mr. Ma Lixiong and Mr. Jiang Feng) and three independent non-executive directors (Mr. Tan Bo, Dr. Li Jin and Mr. Hung Tak Wai).

The company will disclose the audited annual results following board approval on the scheduled date.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1152794578"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152794578\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152794578?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 18:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152794578","market":"hk","top_or_hot":-1,"title":"HighTide Therapeutics-B (2511) Schedules 27 March 2026 Board Meeting to Approve FY 2025 Audited Results","media":"Bulletin Express","content":"<p>HighTide Therapeutics, Inc. (HIGHTIDE-B, 2511) has announced that its board of directors will convene on Friday, 27 March 2026. The primary agenda is to review and approve the audited consolidated financial results for the year ended 31 December 2025 and authorise their publication. Additional routine business matters may also be addressed at the meeting.</p>\n<p>The board currently consists of two executive directors (Dr. Liu Liping and Ms. Yu Meng), three non-executive directors (Dr. Zhu Xun, Mr. Ma Lixiong and Mr. Jiang Feng) and three independent non-executive directors (Mr. Tan Bo, Dr. Li Jin and Mr. Hung Tak Wai).</p>\n<p>The company will disclose the audited annual results following board approval on the scheduled date.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HighTide Therapeutics-B (2511) Schedules 27 March 2026 Board Meeting to Approve FY 2025 Audited Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHighTide Therapeutics-B (2511) Schedules 27 March 2026 Board Meeting to Approve FY 2025 Audited Results\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-03-13 18:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>HighTide Therapeutics, Inc. (HIGHTIDE-B, 2511) has announced that its board of directors will convene on Friday, 27 March 2026. The primary agenda is to review and approve the audited consolidated financial results for the year ended 31 December 2025 and authorise their publication. Additional routine business matters may also be addressed at the meeting.</p>\n<p>The board currently consists of two executive directors (Dr. Liu Liping and Ms. Yu Meng), three non-executive directors (Dr. Zhu Xun, Mr. Ma Lixiong and Mr. Jiang Feng) and three independent non-executive directors (Mr. Tan Bo, Dr. Li Jin and Mr. Hung Tak Wai).</p>\n<p>The company will disclose the audited annual results following board approval on the scheduled date.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02511","symbol_name":"君聖泰醫藥-B","start_time":0,"source_url":"","article_id":"1152794578","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152794578","pubTimestamp":1773396254,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"HighTide Therapeutics, Inc. (HIGHTIDE-B, 2511) has announced that its board of directors will convene on Friday, 27 March 2026. The primary agenda is to review and approve the audited consolidated...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02511":"君圣泰医药-B"},"translate_title":"HighTide Therapeutics-B(2511)计划于2026年3月27日召开董事会会议，批准2025财年经审计业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02511":1},"content_text":"HighTide Therapeutics, Inc. (HIGHTIDE-B, 2511) has announced that its board of directors will convene on Friday, 27 March 2026. The primary agenda is to review and approve the audited consolidated financial results for the year ended 31 December 2025 and authorise their publication. Additional routine business matters may also be addressed at the meeting.\nThe board currently consists of two executive directors (Dr. Liu Liping and Ms. Yu Meng), three non-executive directors (Dr. Zhu Xun, Mr. Ma Lixiong and Mr. Jiang Feng) and three independent non-executive directors (Mr. Tan Bo, Dr. Li Jin and Mr. Hung Tak Wai).\nThe company will disclose the audited annual results following board approval on the scheduled date.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}